STOCK TITAN

[8-K] 23andMe Holding Co. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.
false --03-31 0001804591 0001804591 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Chrome Holding Co.

(Exact name of registrant as specified in its charter)

         
Delaware   001-39587   87-1240344

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

870 Market Street, Room 415

San Francisco, California 94102

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (650) 938-6300

 

23andMe Holding Co.

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

         
Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
         

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

   

 

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

On and effective as of August 14, 2025, 23andMe Holding Co., a Delaware corporation (the “Company”), filed a certificate of amendment (the “CoI Amendment”) amending the Company’s Certificate of Incorporation (as amended, the “CoI”), with the Secretary of State of the State of Delaware to change its name from “23andMe Holding Co.” to “Chrome Holding Co.” (the “Name Change”). The Name Change does not affect the rights of the Company’s stockholders, and there were no other changes to the CoI.

The foregoing description of the CoI Amendment is qualified in its entirety by reference to copy of the full text of the CoI Amendment, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

Exhibit
No.
 

Description of Exhibit

   
3.1.   Certificate of Amendment to the Certificate of Incorporation
     
104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHROME HOLDING CO.  
       
Date: August 15, 2025 By: /s/ Joseph Selsavage  
    Name: Joseph Selsavage  
    Title: Interim Chief Executive Officer, and Chief Financial and Accounting Officer  

 

 

 

   

 

23Andme Holding Co

NASDAQ:ME

ME Rankings

ME Latest News

ME Latest SEC Filings

ME Stock Data

82.91M
16.32M
17.27%
26.08%
6.66%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States
SUNNYVALE